1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Shanghai Shen Lian Biomedical Corporation

Shanghai Shen Lian Biomedical Corporation

688098.SS
Shanghai Shen Lian Biomedical CorporationCN flagShanghai Stock Exchange
9.50
CNY
-0.38
- -
3.90BMarket Cap

Total Valuation

Shanghai Shen Lian Biomedical Corporation carries a market capitalization of 3.90B, placing it among publicly traded companies globally. Its enterprise value stands at 1.74B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap3.90B
Enterprise Value1.74B

Share Statistics

Shanghai Shen Lian Biomedical Corporation currently has 410.64M shares outstanding.

Shares Outstanding410.64M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

The price-to-sales ratio is 6.18, and the price-to-book ratio stands at 2.30.

PE RatioN/A
PS Ratio6.18
PB Ratio2.30
P/TBV Ratio1.45
P/FCF Ratio21.91
P/OCF RatioN/A

Enterprise Valuation

EV / Sales5.84
EV / EBITDAN/A
EV / EBITN/A
EV / FCF20.67

Financial Position

Shanghai Shen Lian Biomedical Corporation maintains a current ratio of 4.44, meaning it holds 4.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 1.08, indicating moderate leverage, while an interest coverage ratio of -20.18 demonstrates limited ability to service its debt obligations.

Current Ratio4.44
Quick Ratio1.11
Debt / Equity1.08
Debt / EBITDA-5.52
Interest Coverage-20.18

Financial Efficiency

Return on Equity (ROE)-2.84
Return on Assets (ROA)-1.49
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)N/A
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover1.12

Taxes

Income Tax-8.55M
Effective Tax RateN/A

Stock Price Statistics

Shanghai Shen Lian Biomedical Corporation's stock has gained approximately 54.97553% over the past 52 weeks. The 50-day moving average sits at 8.49, while the 200-day moving average is 9.34.

Beta (5Y)N/A
52-Week Price Change54.97553%
50-Day Moving Average8.49
200-Day Moving Average9.34
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Shanghai Shen Lian Biomedical Corporation generated 298.76M in revenue and converted that into -23.10M in net income, yielding earnings per share of -0.09. EBITDA reached -2.75M, while operating income came in at -2.75M.

Revenue298.76M
Gross Profit180.57M
Operating Income-2.75M
Pretax Income-35.91M
Net Income-23.10M
EBITDA-2.75M
EBIT-2.75M
Earnings Per Share (EPS)-0.09

Balance Sheet

Shanghai Shen Lian Biomedical Corporation holds 128.96M in cash and equivalents against 15.19M in total debt, resulting in a net debt position of -39.63M. Total book value stands at 802.50M, with working capital of 398.56M providing operational flexibility.

Cash & Cash Equivalents128.96M
Total Debt15.19M
Net Debt-39.63M
Equity (Book Value)802.50M
Book Value Per Share2.66
Working Capital398.56M

Cash Flow

After subtracting -84.23M in capital expenditures, free cash flow totaled -84.23M - equivalent to -0.28 per share.

Operating Cash FlowN/A
Capital Expenditures-84.23M
Free Cash Flow-84.23M
FCF Per Share-0.28

Margins

Shanghai Shen Lian Biomedical Corporation operates with a gross margin of 60.44, reflecting its pricing power and cost economics. The operating margin of -0.92 and net profit margin of -7.73 provide insight into operational efficiency.

Gross Margin60.44
Operating Margin-0.92
Pretax Margin-12.02
Profit Margin-7.73
EBITDA Margin-0.92

Dividends & Yields

The company's payout ratio of -4.66 indicates the proportion of earnings distributed to shareholders.

Dividend Per Share0.00
Dividend YieldN/A
Payout Ratio-4.66
Shareholder Yield0.47
FCF Yield4.56

Scores

Shanghai Shen Lian Biomedical Corporation posts an Altman Z-Score of 9.61, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score9.61